Compare DexCom, Inc. (DXCM) vs Nuwellis Inc (NUWE) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

Nuwellis (NUWE) trades at $3.22, up 15% in the last 24 hours, following a recent 35:1 reverse stock split executed on June 26, 2026. The medical technology company shows a mixed financial picture with a strong gross margin of 65.47% but significant net losses and negative profitability ratios. Recent news highlights expansion in pediatric care, new patent awards, and a $6 million public offering closed in June 2026 to fund operations. Technical indicators are predominantly bearish, with moving averages signaling strong selling pressure.

The outlook remains challenging due to persistent operating losses and negative cash flow, offset by strategic pediatric market expansion and new product innovation. Investment opportunity hinges on the company's ability to translate its high gross margin and recent capital raise into sustainable revenue growth and eventual profitability. Key risks include continued cash burn, execution of commercial strategy, and reliance on financing activities to fund operations.